Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · HIV/AIDS

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 7 · 100%High 0 · 0%

Primary outcome: partial clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + ABV probably leads to higher clinical response ‐ partial response compared with HAART alone (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 1.71 [1.01, 2.91]
1 study · 100 participants
Moderate

Complete or partial remission · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + ABV probably leads to higher clinical response ‐ overall response (complete and partial) compared with HAART alone (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 1.78 [1.16, 2.72]
1 study · 100 participants
Moderate

All‐cause mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + ABV showed no clear difference in mortality compared with HAART alone (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 0.92 [0.45, 1.88]
1 study · 100 participants
Moderate

Progressive disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + ABV probably leads to lower progressive disease compared with HAART alone (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 0.1 [0.01, 0.75]
1 study · 100 participants
Moderate

Clinical response ‐ complete response · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + ABV showed no clear difference in clinical response ‐ complete response compared with HAART alone (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 2 [0.64, 6.22]
1 study · 100 participants
Moderate

Clinical response ‐ stable disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + ABV probably leads to lower clinical response ‐ stable disease compared with HAART alone (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 0.06 [0, 0.99]
1 study · 100 participants
Moderate

Adverse events · HIV‐infected adults with severe (T1) Kaposi's sarcoma

HAART + ABV showed no clear difference in adverse events compared with HAART alone (moderate certainty).

1 finding from 1 review

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults 2014 · Cochrane Headline outcomes only
RR 0.88 [0.59, 1.32]
1 study · 100 participants
Moderate